Biotech Showcase™ 2017: Advancing neurokinin receptor antagonists in respiratory and women’s health

January 24, 2017
Starting the year with a cash injection of GDP 23 million, 2012 GSK spin-out NeRRe Therapeutics intends to advance its neurokinin receptor antagonist pipeline towards late-stage clinical development. Speaking at the 2017 Biotech Showcase, NeRRe CEO Dr. Mary Kerr tells Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, how the company plans to generate Phase II data on orvepitant, a chronic respiratory candidate; and to advance NT-814 as a potential non-hormonal treatment of distressing post-menopausal vasomotor symptoms.
Previous Video
Biotech Showcase™ 2017: Chinese capital accesses Western innovation to create homegrown industry
Biotech Showcase™ 2017: Chinese capital accesses Western innovation to create homegrown industry

With the Chinese market growing at 10–15% a year, it is poised to be world’s largest by 2026. Tony Chu, co-...

Next Video
Biotech Showcase™ 2017: Q BioMed plans to accelerate up to four more assets
Biotech Showcase™ 2017: Q BioMed plans to accelerate up to four more assets

Established in June 2015, Q BioMed, the NYC-based biomedical acceleration development company, is looking t...